Schwalbe R S, McIntosh A C, Qaiyumi S, Johnson J A, Johnson R J, Furness K M, Holloway W J, Steele-Moore L
Department of Pathology, University of Maryland School of Medicine, Baltimore, USA.
Antimicrob Agents Chemother. 1996 Oct;40(10):2416-9. doi: 10.1128/AAC.40.10.2416.
The in vitro activities of LY333328 were compared with those of vancomycin, teicoplanin, and quinupristin-dalfopristin (Synercid) against 219 strains of enterococci and staphylococci, including vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus. MICs and MBCs were determined by a microtiter dilution protocol. LY333328 demonstrated superior activity against vancomycin-resistant enterococci and was the only antibiotic which was bactericidal. Its potency was comparable or superior to those of other antibiotics tested against methicillin-resistant staphylococci.
将LY333328的体外活性与万古霉素、替考拉宁和奎奴普丁-达福普汀（Synercid）对219株肠球菌和葡萄球菌的活性进行了比较，其中包括耐万古霉素肠球菌和耐甲氧西林金黄色葡萄球菌。通过微量滴定稀释法测定最低抑菌浓度（MICs）和最低杀菌浓度（MBCs）。LY333328对耐万古霉素肠球菌表现出更强的活性，并且是唯一具有杀菌作用的抗生素。其效力与针对耐甲氧西林葡萄球菌测试的其他抗生素相当或更强。
